Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone By Ogkologos - June 24, 2025 951 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes MOST POPULAR Students Invent Disposable Core Biopsy Needle to Make the Procedure Cheaper May 21, 2019 Longer Duration of Treatment with ICIs Associated with a Higher Rate... March 5, 2025 New Drugs, New Side Effects: Complications of Cancer Immunotherapy May 10, 2019 FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum April 13, 2022 Load more HOT NEWS No OS Benefit for Active Maintenance Treatment with Olaparib Relative to... Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable... Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality...
